Inventor · disambiguated record
Nabil Hanna
Also filed as: HANNA NABIL · HANNA NABIL S
51 granted patents·41 pending applications·6,424 citations·filing 1980–2010
99Inventor score
Files withBIOGEN IDEC INC44IDEC PHARMA CORP20SMITHKLINE BECKMAN CORP6SMITHKLINE BEECHAM CORP4BLACK AMELIA2
Top patents by PatentIndex Score
92 records- 0199US7422739B2Anti-CD20 antibodiesBIOGEN IDEC INC·Filed 2001·Granted Sep 9, 2008·166 cites·13 claims
- 0299US5736137ATherapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaIDEC PHARMA CORP·Filed 1993·Granted Apr 7, 1998·1.6k cites·6 claims
- 0398US6896885B2Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphomaBIOGEN IDEC INC·Filed 2001·Granted May 24, 2005·143 cites·29 claims
- 0498US6399061B1Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphomaIDEC PHARMA CORP·Filed 1995·Granted Jun 4, 2002·254 cites·7 claims
- 0598US5843439ATherapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaFiled 1995·Granted Dec 1, 1998·336 cites·7 claims
- 0698US5776456ATherapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaIDEC PHARMA CORP·Filed 1995·Granted Jul 7, 1998·527 cites·14 claims
- 0798US5693780ARecombinant antibodies for human therapyIDEC PHARMA CORP·Filed 1995·Granted Dec 2, 1997·485 cites·16 claims
- 0898US5658570ARecombinant antibodies for human therapyIDEC PHARMA CORP·Filed 1995·Granted Aug 19, 1997·695 cites·38 claims
- 0997US6682734B1Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphomaIDEC PHARMA CORP·Filed 1995·Granted Jan 27, 2004·176 cites·13 claims
- 1097US6136310ARecombinant anti-CD4 antibodies for human therapyIDEC PHARMA CORP·Filed 1995·Granted Oct 24, 2000·186 cites·16 claims
- 1197US6113898AHuman B7.1-specific primatized antibodies and transfectomas expressing said antibodiesIDEC PHARMA CORP·Filed 1995·Granted Sep 5, 2000·207 cites·11 claims
- 1297US5750105ARecombinant antibodies for human therapyIDEC PHARMA CORP·Filed 1995·Granted May 12, 1998·318 cites·10 claims
- 1397US4686231AInhibition of 5-lipoxygenase productsSMITHKLINE BECKMAN CORP·Filed 1986·Granted Aug 11, 1987·130 cites·37 claims
- 1496US7381560B2Expression and use of anti-CD20 antibodiesBIOGEN IDEC INC·Filed 2001·Granted Jun 3, 2008·45 cites·10 claims
- 1596US6001358AHumanized antibodies to human gp39, compositions containing thereofIDEC PHARMA CORP·Filed 1995·Granted Dec 14, 1999·125 cites·12 claims
- 1696US5756096ARecombinant antibodies for human therapyIDEC PHARMA CORP·Filed 1995·Granted May 26, 1998·175 cites·6 claims
- 1796US5681722ARecombinant antibodies for human therapyIDEC PHARMA CORP·Filed 1995·Granted Oct 28, 1997·158 cites·8 claims
- 1895US7192585B2CD80 specific antibodiesBIOGEN IDEC INC·Filed 2005·Granted Mar 20, 2007·17 cites·20 claims
- 1993US7744877B2Expression and use of anti-CD20 AntibodiesBIOGEN IDEC INC·Filed 2002·Granted Jun 29, 2010·38 cites·8 claims
- 2093US7338658B2Recombinant anti-CD4 antibodies for human therapyBIOGEN IDEC INC·Filed 2002·Granted Mar 4, 2008·36 cites·7 claims
- 2192US7294753B2Method for preparing anti-MIF antibodiesBIOGEN IDEC INC·Filed 2005·Granted Nov 13, 2007·20 cites·12 claims
- 2292US6897044B1Production of tetravalent antibodiesBIOGEN IDEC INC·Filed 1999·Granted May 24, 2005·133 cites·32 claims
- 2392US6893638B2Methods for treating b cell lymphoma using CD80-specific antibodiesFiled 2001·Granted May 17, 2005·40 cites·5 claims
- 2491US7491393B2Methods of inhibiting IL-2 production by T cells by administering 7C10 and 16C10 CD80-specific antibodiesBIOGEN IDEC INC·Filed 2007·Granted Feb 17, 2009·4 cites·20 claims
- 2591US7175847B1Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4BIOGEN IDEC INC·Filed 2000·Granted Feb 13, 2007·13 cites·45 claims
- 2690US7153508B2Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4BIOGEN IDEC INC·Filed 2002·Granted Dec 26, 2006·19 cites·26 claims
- 2789US6998125B2Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesisBIOGEN IDEC INC·Filed 2001·Granted Feb 14, 2006·25 cites·19 claims
- 2888US7510712B2Methods of treating rheumatoid arthritis with 7C10 and 16C10 CD80-specific antibodiesBIOGEN IDEC INC·Filed 2007·Granted Mar 31, 2009·5 cites·20 claims
- 2987US7425447B2Host cells expressing 7C10 and 16C10 CD80-specific antibodiesBIOGEN IDEC INC·Filed 2006·Granted Sep 16, 2008·5 cites·44 claims
- 3087US7319139B2TAG-72 specific CH2 domain deleted antibodiesBIOGEN IDEC INC·Filed 2002·Granted Jan 15, 2008·25 cites·22 claims
- 3186US7417128B27C10 and 16C10 CD80-specific antibodiesBIOGEN IDEC INC·Filed 2006·Granted Aug 26, 2008·5 cites·13 claims
- 3285US7122187B2Treating autoimmune diseases with humanized anti-CD40L antibodyBIOGEN IDEC INC·Filed 2002·Granted Oct 17, 2006·23 cites·8 claims
- 3385US7074406B2Treating allergic diseases with humanized anti-CD40L antibodyBIOGEN IDEC INC·Filed 2002·Granted Jul 11, 2006·14 cites·9 claims
- 3485US5317019AInhibition of interleukin-1 and tumor necrosis factor production by monocytes and/or macrophagesSMITHKLINE BEECHAM CORP·Filed 1990·Granted May 31, 1994·70 cites·4 claims
- 3585US4794114AInhibition of interleukin-1 production by monocytes and/or macrophagesSMITHKLINE BECKMAN CORP·Filed 1987·Granted Dec 27, 1988·37 cites·20 claims
- 3681US7510713B2Methods of inducing immunosuppression by administering 7C10 and 16C10 CD80-specific antibodiesBIOGEN IDEC INC·Filed 2007·Granted Mar 31, 2009·1 cites·20 claims
- 3780US7414123B2Nucleic acids encoding 7C10 and 16C10 CD80-specific antibodiesBIOGEN IDEC INC·Filed 2006·Granted Aug 19, 2008·1 cites·16 claims
- 3880US6440418B1Methods of treating autoimmune diseases with gp39-specific antibodiesIDEC PHARMA CORP·Filed 1997·Granted Aug 27, 2002·36 cites·16 claims
- 3979US4719218APyrrolo[1,2-a]imidazole and pyrrolo[1,2-a]pyridine derivatives and their use as 5-lipoxygenase pathway inhibitorSMITHKLINE BECKMAN CORP·Filed 1986·Granted Jan 12, 1988·26 cites·32 claims
- 4078US7501264B2Methods of producing 7C10 and 16C10 CD80-specific antibodiesBIOGEN IDEC INC·Filed 2007·Granted Mar 10, 2009·1 cites·23 claims
- 4178US7452534B1Recombinant anti-CD4 antibodies for human therapyBIOGEN IDEC INC·Filed 2000·Granted Nov 18, 2008·7 cites·18 claims
- 4276US6709654B1Treatment of psoriasis using anti-B7.1 (CD80) antibodiesFiled 1999·Granted Mar 23, 2004·28 cites·7 claims
- 4373US7323170B2Anti-CD80 antibodiesBIOGEN IDEC INC·Filed 2004·Granted Jan 29, 2008·4 cites·30 claims
- 4471US2008213260A1Use of cd23 antagonists for the treatment of neoplastic disordersBIOGEN IDEC INC·Filed 2007·Application pending·0 cites
- 4571US2009124791A1Identification of unique binding interactions between certain antibodies and the human b7.1 and b7.2 co-stimulatory antigensBIOGEN IDEC INC·Filed 2008·Application pending·0 cites
- 4671US2008213167A1Use of cd23 antagonists for the treatment of neoplastic disordersBIOGEN IDEC INC·Filed 2007·Application pending·0 cites
- 4769US2008226626A1Immunoregulatory antibodies and uses thereofBIOGEN IDEC INC·Filed 2007·Application pending·0 cites
- 4868US5145858APyrrolo [1,2-a] imidazole and imidazo [1,2a] pyridine derivatives and their use as 5-lipoxygenase pathway inhibitorsSMITHKLINE BEECHAM CORP·Filed 1991·Granted Sep 8, 1992·13 cites·15 claims
- 4966US2009221036A1Recombinant anti-cd4 antibodies for human therapyBIOGEN IDEC INC·Filed 2008·Application pending·0 cites
- 5066US2006171950A1Use of cd23 antagonists for the treatment of neoplastic disordersBIOGEN IDEC INC·Filed 2006·Application pending·0 cites
Showing the top 50 of 92 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Nabil Hanna files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →